12/19/2024
3:20 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/19/2024
3:20 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/13/2024
6:52 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Dorsey Brian (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/13/2024
6:53 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Chakma Justin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/13/2024
4:24 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Chakma Justin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/12/2024
4:41 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Chakma Justin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/12/2024
4:02 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Chakma Justin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
|
12/11/2024
5:30 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/11/2024
5:30 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/11/2024
4:31 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Dorsey Brian (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/10/2024
3:48 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Chakma Justin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/10/2024
10:15 AM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Lowenthal Richard E (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/09/2024
4:43 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/09/2024
4:25 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/09/2024
11:38 AM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Shawver Laura (Reporting)
| Form 144/A | |
12/06/2024
6:15 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Chakma Justin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/06/2024
4:30 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Chakma Justin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/05/2024
4:06 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Chakma Justin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/03/2024
4:25 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Chakma Justin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/02/2024
6:01 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Chakma Justin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/02/2024
5:22 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Shawver Laura (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/02/2024
3:42 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Karas Eric (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/27/2024
3:11 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Chakma Justin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/21/2024
3:30 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/21/2024
3:30 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/15/2024
2:21 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Chakma Justin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/13/2024
7:16 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
DEERFIELD MANAGEMENT COMPANY, L.P. (0001009258) (Reporting)
Deerfield Mgmt III, L.P. (Reporting)
Deerfield Mgmt IV, L.P. (Reporting)
Deerfield Private Design Fund III, L.P. (Reporting)
Deerfield Private Design Fund IV, L.P. (Reporting)
Flynn James E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/13/2024
6:02 AM | Silverback Therapeutics (Filer)
ARS Pharmaceuticals, Inc. (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
11/13/2024
6:00 AM | Silverback Therapeutics (Filer)
ARS Pharmaceuticals, Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/17/2024
3:30 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/17/2024
3:30 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/17/2024
3:30 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Scott Kathleen D. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/16/2024
3:01 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Scott Kathleen D. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/15/2024
10:28 AM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Tanimoto Sarina (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/15/2024
6:02 AM | Silverback Therapeutics (Filer)
ARS Pharmaceuticals, Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/10/2024
3:27 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/10/2024
3:28 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/23/2024
3:15 PM | Silverback Therapeutics (Filer)
ARS Pharmaceuticals, Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
09/19/2024
3:26 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/19/2024
3:29 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/19/2024
3:30 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Karas Eric (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis (Ad) Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%.
Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with … Find out details on these three critical Nvidia partners immediately. |
09/18/2024
3:06 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Karas Eric (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/12/2024
3:24 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/12/2024
3:25 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/10/2024
9:31 AM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Lowenthal Richard E (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/28/2024
3:30 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Thompson Peter A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/23/2024
5:41 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Thompson Peter A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/23/2024
5:38 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
ORBIMED ADVISORS LLC (Reporting)
OrbiMed Capital GP VI LLC (Reporting)
ORBIMED CAPITAL LLC (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/21/2024
5:43 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
ORBIMED CAPITAL LLC (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/21/2024
5:47 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/21/2024
5:48 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/21/2024
5:49 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Scott Kathleen D. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/21/2024
5:51 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Karas Eric (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/21/2024
5:51 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Dorsey Brian (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/20/2024
3:18 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Scott Kathleen D. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/15/2024
3:30 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/15/2024
3:30 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/15/2024
3:30 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Dorsey Brian (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/12/2024
6:59 AM | Silverback Therapeutics (Filer)
ARS Pharmaceuticals, Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
07/18/2024
3:30 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/18/2024
3:30 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/16/2024
11:07 AM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Tanimoto Sarina (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/11/2024
4:03 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/11/2024
4:04 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/28/2024
2:15 PM | Silverback Therapeutics (Filer)
ARS Pharmaceuticals, Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/28/2024
5:46 AM | Silverback Therapeutics (Filer)
ARS Pharmaceuticals, Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/24/2024
4:06 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Dadoo Rajeev (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/24/2024
4:13 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Kolchinsky Peter (Reporting)
RA Capital Healthcare Fund LP (Reporting)
RA CAPITAL MANAGEMENT, L.P. (Reporting)
RA Capital Nexus Fund II, L.P. (Reporting)
Shah Rajeev M. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/21/2024
4:00 PM | Silverback Therapeutics (Filer)
ARS Pharmaceuticals, Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/17/2024
7:47 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Pratik Shah Living Trust dated June 15, 2011 (Filed by)
| Form SC 13D/A | |
06/17/2024
5:39 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Shah Pratik (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/13/2024
3:30 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/11/2024
6:18 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Pratik Shah Living Trust dated June 15, 2011 (Filed by)
| Form SC 13D/A | |
06/11/2024
10:36 AM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
Lowenthal Richard E (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
06/07/2024
8:09 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Pratik Shah Living Trust dated June 15, 2011 (Reporting)
Shah Pratik (Reporting)
| Form 4/A | |
06/07/2024
8:11 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Shah Pratik (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/06/2024
3:32 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Pratik Shah Living Trust dated June 15, 2011 (Reporting)
Shah Pratik (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/16/2024
6:51 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/16/2024
6:52 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/10/2024
6:01 AM | Silverback Therapeutics (Filer)
ARS Pharmaceuticals, Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/09/2024
5:57 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/09/2024
5:59 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/09/2024
3:08 PM | Silverback Therapeutics (Filer)
ARS Pharmaceuticals, Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/24/2024
5:17 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/24/2024
5:18 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/22/2024
6:22 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/22/2024
6:23 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/17/2024
5:40 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/17/2024
5:42 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/10/2024
4:36 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/10/2024
4:39 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis (Ad) Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%.
Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with … Find out details on these three critical Nvidia partners immediately. |
03/29/2024
3:14 PM | Silverback Therapeutics (Subject)
ARS Pharmaceuticals, Inc. (Subject)
RA CAPITAL MANAGEMENT, L.P. (Filed by)
| Form SC 13D/A | |
03/27/2024
6:37 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Kolchinsky Peter (Reporting)
RA Capital Healthcare Fund LP (Reporting)
RA CAPITAL MANAGEMENT, L.P. (Reporting)
RA Capital Nexus Fund II, L.P. (Reporting)
Shah Rajeev M. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/26/2024
5:47 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/26/2024
5:48 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/21/2024
8:50 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/21/2024
8:51 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/21/2024
4:08 PM | Silverback Therapeutics (Filer)
ARS Pharmaceuticals, Inc. (Filer)
| Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
03/15/2024
6:52 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/15/2024
6:55 PM | Silverback Therapeutics (Issuer)
ARS Pharmaceuticals, Inc. (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
Free SBTX Stock Alerts